ArticleIranian journal of microbiology2023
Antiviral activity of biosynthesized copper nanoparticle by
Article in Iranian journal of microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- Copper/Copper Oxide Nanoparticles: Biological Synthesis, Characterization and Potential Biomedical Applications: Advances and Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Antiviral activity of biogenic silver nanoparticles against HSV-1: integrating computational modeling and experimental validation.Iranian journal of microbiology · 2026Article
- Phyto mediated synthesis of copper oxide nanoparticles with Zingiber officinale: comprehensive bioactivity assessment against bacterial pathogens, cancer, and viruses.BMC biotechnology · 2026Article
- Harnessing Copper Nanoparticles for Antimicrobial Applications: Advances and Challenges.Antibiotics (Basel, Switzerland) · 2025Review
- Copper nanoparticles as a novel therapeutic approach for canine distemper virus: Clinical, hematological, and biochemical evidence from naturally infected dogs.Veterinary world · 2025Article
- UiO-66 nanoparticles combat influenza A virus in mice by activating the RIG-I-like receptor signaling pathway.Journal of nanobiotechnology · 2024Article
- Article
- Biosynthesis of Copper Nanoparticles with Medicinal Plants Extracts: From Extraction Methods to Applications.Micromachines · 2023Review
- Copper and Copper-Based Nanoparticles in Medicine-Perspectives and Challenges.Molecules (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: The interaction between nanoparticles (NPs) and viruses is attracting interest because of the antiviral potential of NPs. This study aims to investigate the antiviral potential of NPs against Herpes simplex virus types 1 (HSV-1). Materials and Methods: Molecular docking studies were conducted by Molegro virtual docker software. An extract of Results: Docking results confirmed that NPs could interact with the HSV-1 glycoproteins and prevent viral entry. MTT assay results illustrated that the minimum non-toxic concentration (MNTD) of CuNPs is 100 μg/ml which did not exhibit antiviral properties. Employing a noncytotoxic concentration of FeNPs (300 mg/ml) in combination with cytotoxic concentration of CuNPs (300 μg / ml), eliminated the cytotoxicity effects of CuNPs. Exposure of the virus with the combination of CuNPs and FeNPs resulted in 4.5 log10 TCID Conclusion: The results highlight that combination of CuNPs and FeNPs have antiviral activity against HSV-1. Moreover, FeNPs demonstrated antiviral properties against HSV-1 separately.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.